TERN 301
Alternative Names: TERN-301Latest Information Update: 28 Feb 2024
At a glance
- Originator Terns Pharmaceuticals
- Class Anti-inflammatories; Hepatoprotectants; Small molecules
- Mechanism of Action MAP kinase kinase kinase 5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for research development in Non-alcoholic-fatty-liver-disease in USA (PO)
- 28 Feb 2024 No recent reports of development identified for research development in Non-alcoholic-steatohepatitis in USA (PO)
- 01 Mar 2023 TERN 301 is available for licensing as of 01 Mar 2023. https://www.ternspharma.com/ 3781244